| 1 |
34987640 | Tumor-infiltrating lymphocytes are functionally inactivated by CD90+ stromal cells and reactivated by combined Ibrutinib and Rapamycin in human pleural mesothelioma. | 2022 |
2 |
| 2 |
32640487 | BTK/ITK dual inhibitors: Modulating immunopathology and lymphopenia for COVID-19 therapy. | 2021 Jan |
1 |
| 3 |
32683672 | Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients. | 2021 Jan 15 |
3 |
| 4 |
33593794 | Enhancing the Generation of Eomeshi CD8+ T Cells Augments the Efficacy of OX40- and CTLA-4-Targeted Immunotherapy. | 2021 Apr |
2 |
| 5 |
33981831 | Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma. | 2021 Jun 25 |
2 |
| 6 |
34000704 | Design and synthesis of novel substituted benzyl pyrrolopyrimidine derivatives as selective BTK inhibitors for treating mantle cell lymphoma. | 2021 Jul |
1 |
| 7 |
34046681 | BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL. | 2021 Nov 11 |
2 |
| 8 |
34065833 | The Role of Novel Agents in Treating CLL-Associated Autoimmune Hemolytic Anemia. | 2021 May 12 |
1 |
| 9 |
34508613 | Bortezomib enhances the anti-cancer effect of the novel Bruton's tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK. | 2021 Sep 10 |
4 |
| 10 |
32306816 | The effect of ibrutinib on neutrophil and γδ T cell functions. | 2020 Oct |
1 |
| 11 |
33043320 | Ibrutinib for chronic lymphocytic leukemia in the setting of respiratory failure from severe COVID-19 infection: Case report and literature review. | 2020 Sep 20 |
2 |
| 12 |
30742126 | Proliferation tracing with single-cell mass cytometry optimizes generation of stem cell memory-like T cells. | 2019 Mar |
1 |
| 13 |
31013298 | Structural and diffusion weighted MRI demonstrates responses to ibrutinib in a mouse model of follicular helper (Tfh) T-cell lymphoma. | 2019 |
1 |
| 14 |
31025232 | Genetic Deficiency and Biochemical Inhibition of ITK Affect Human Th17, Treg, and Innate Lymphoid Cells. | 2019 May |
1 |
| 15 |
31511358 | Dissection of the Effects of JAK and BTK Inhibitors on the Functionality of Healthy and Malignant Lymphocytes. | 2019 Oct 15 |
1 |
| 16 |
31861854 | Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy against CLL. | 2019 Dec 20 |
2 |
| 17 |
31869418 | Ibrutinib, but not zanubrutinib, induces platelet receptor shedding of GPIb-IX-V complex and integrin αIIbβ3 in mice and humans. | 2019 Dec 23 |
1 |
| 18 |
29285806 | Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies. | 2018 Apr |
1 |
| 19 |
29669753 | Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma. | 2018 Apr 24 |
5 |
| 20 |
28714866 | Ibrutinib treatment improves T cell number and function in CLL patients. | 2017 Aug 1 |
2 |
| 21 |
28924018 | Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. | 2017 Nov 23 |
1 |
| 22 |
26942065 | Ibrutinib enhances IL-17 response by modulating the function of bone marrow derived dendritic cells. | 2016 |
1 |
| 23 |
27590878 | Second-generation inhibitors of Bruton tyrosine kinase. | 2016 Sep 2 |
1 |
| 24 |
27678331 | Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth. | 2016 Dec |
1 |
| 25 |
27802969 | Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. | 2016 Dec 22 |
3 |